Tag Archives: personalized medicine

Delivering on the Promise of Personalized Medicine

185x185_ad_btn_home

As sequencing moves out of the lab and into the clinic, a host of players must get involved to make our collective promises of personalized medicine a reality. CEOs, entrepreneurs, researchers, clinicians, regulators and payers need to work together to take on the next challenges in the implementation of personalized medicine. Some of those challenges include: Cost vs. Benefit: How do we define and benefit from transformational technologies? Form vs. Function: What about the less Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Pharmaceuticals Play a Key Role in Value-Based Care

Dan Leonard

By Dan Leonard, President, National Pharmaceutical Council Public and private sector health care stakeholders have been struggling with how best to achieve the triple aim of better care for individuals, improved health for populations, and slower cost growth. Figuring out the best health care delivery structures and approaches is a complex challenge with many variables and moving parts. That’s why there is a great deal of debate and research into what changes can support the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Mayo v. Prometheus: Thought Leaders Express Concern and Evaluate the Impact

Cells

The Mayo v. Prometheus event hosted at George Washington School of Law with the Biotechnology Industry Organization created an opportunity for a panel of thought leaders to distill meaning from the case, the impact on personalized medicine, and possible solutions to the Court created problem.* Is the decision a game-changer? Judge Paul R. Michel, former Chief Judge of the Court of Appeals for the Federal Circuit handling patent cases, concluded that the Mayo v. Prometheus Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: ,

Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward

gw-law

Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward is a public round-table event hosted by the Biotechnology Industry Organization and the George Washington University Law School. Guest speakers at the round-table will discuss implementation of the Prometheus decision in patent prosecution practice, in examination guidance in the United States Patent Office, and in patent litigation.  Speakers will also discuss the implications of the decision on personalized medicine and possible ways forward.  Speakers include: The Hon. Paul Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO’s Prometheus v. Mayo Amicus Brief Filed

prometheus

BIO filed an amicus brief in the Prometheus v. Mayo Clinic case.  In this case the Supreme Court is being asked to decide whether diagnostic and personalized medicine claims that depend on a correlation of observed phenomena should be excluded from the patent system at the outset, as patent-ineligible abstract ideas or “laws of nature.” BIO’s brief argues that these judicially-created exclusions from patent-eligibility have traditionally been used only under narrow circumstances, and that their Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,